Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma

Shiba,Hiroaki; Horiuchi,Takashi; Sakamoto,Taro; Furukawa,Kenei; Shirai,Yoshihiro; Iida,Tomonori; Fujiwara,Yuki; Haruki,Koichiro; Yanaga,Katsuhiko

doi:10.3892/ol.2017.6104

Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma

Authors:
- Hiroaki Shiba
- Takashi Horiuchi
- Taro Sakamoto
- Kenei Furukawa
- Yoshihiro Shirai
- Tomonori Iida
- Yuki Fujiwara
- Koichiro Haruki
- Katsuhiko Yanaga
View Affiliations

Affiliations: Department of Surgery, The Jikei University School of Medicine, Minato‑ku, Tokyo 105‑8461, Japan
Published online on: April 28, 2017 https://doi.org/10.3892/ol.2017.6104
Pages: 293-298

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Systemic inflammation, as evidenced by the Glasgow prognostic score (GPS), predicts cancer‑specific survival in various cancer types. The aim of this study was to evaluate the significance of the GPS in the therapeutic outcome of the patient following surgical resection for hepatocellular carcinoma. In total, 144 patients underwent surgical resection for hepatocellular carcinoma. For the assessment of systemic inflammatory response using the GPS, patients were classified into three groups: Patients with normal serum albumin (<3.5 g/dl) and normal serum C‑reactive protein (CRP) (≤1.0 mg/dl) were classified as GPS 0 (n=76), those with low serum albumin (<3.5 g/dl) or elevated serum CRP (>1.0 mg/dl) were classified as GPS 1 (n=58), and those with low serum albumin (<3.5 g/dl) and elevated serum CRP (>1.0 mg/dl) were classified as GPS 2 (n=10). Retrospectively, the relationship between patient characteristics including GPS, disease‑free as well as overall survival were investigated. In disease‑free survival, GPS 2 (P=0.019), with a tumor number ≥3 (P=0.004), and positive portal or venous invasion (P=0.034) were independent predictors of cancer recurrence in multivariate analysis. In overall survival, GPS 1 (P=0.042), GPS 2 (P<0.001) and positive portal or venous invasion (P<0.001) were independent predictors of poor patient outcome according to multivariate analysis. To conclude, the GPS in patients with hepatocellular carcinoma is an independent prognostic predictor after hepatic resection.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM and Wong J: Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Ann Surg. 234:63–70. 2001. View Article : Google Scholar : PubMed/NCBI
3	Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL and Wong J: Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: A study of a prospective cohort. J Clin Oncol. 19:3037–3044. 2001. View Article : Google Scholar : PubMed/NCBI
4	Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH and Dematteo RP: Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 249:617–623. 2009. View Article : Google Scholar : PubMed/NCBI
5	Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, Maetani S and Tobe T: Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer. 69:913–919. 1992. View Article : Google Scholar : PubMed/NCBI
6	Yanaga K: Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol. 39:919–926. 2004. View Article : Google Scholar : PubMed/NCBI
7	Shiba H, Ishida Y, Wakiyama S, Iida T, Matsumoto M, Sakamoto T, Ito R, Gocho T, Furukawa K, Fujiwara Y, Hirohara S, et al: Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 13:1636–1642. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tandon P and Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
9	McMillian DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI
10	Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ and Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 94:1568–1571. 2006.PubMed/NCBI
11	Hilmy M, Bartlett JM, Underwood MA and McMillan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer. 92:625–627. 2005. View Article : Google Scholar : PubMed/NCBI
12	Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R and Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer. 92:21–23. 2005. View Article : Google Scholar : PubMed/NCBI
13	Lamb GW, Aitchison M, Ramsey S, Housley SL and McMillan DC: Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: Basis of new prognostic scoring systems. Br J Cancer. 106:279–283. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y and Onitsuka T: Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res. 27:3001–3004. 2007.PubMed/NCBI
15	Shiba H, Misawa T, Fujiwara Y, Futagawa Y, Furukawa K, Haruki K, Iwase R, Wakiyama S, Ishida Y and Yanaga K: Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater. Anticancer Res. 33:2715–2721. 2013.PubMed/NCBI
16	Shiba H, Iwase R, Futagawa Y, Futagawa Y, Furukawa K, Haruki K, Iwase R, Iida T and Yanaga K: Glasgow prognostic score predicts therapeutic outcome after surgical resection for gallbladder cancer. World J Surg. 39:753–758. 2015. View Article : Google Scholar : PubMed/NCBI
17	Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T and Yanaga K: The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 4:324–328. 2012.PubMed/NCBI
18	Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M and Sawada T: Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: A retrospective study of 398 Japanese patients. Am J Surg. 203:101–106. 2012. View Article : Google Scholar : PubMed/NCBI
19	Horino K, Beppu T, Kuroki H, Mima K, Okabe H, Nakahara O, Ikuta Y, Chikamoto A, Ishiko T, Takamori H and Baba H: Glasgow prognostic score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol. 18:829–838. 2013. View Article : Google Scholar : PubMed/NCBI
20	Miyagawa S, Makuuchi M, Kawasaki S and Kakazu T: Criteria for safe hepatic resection. Am J Surg. 169:589–594. 1995. View Article : Google Scholar : PubMed/NCBI
21	Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, Fan ST, Yokoyama Y, Crawford M, Makuuchi M, et al: Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 149:680–688. 2011. View Article : Google Scholar : PubMed/NCBI
22	Mangram AJ, Horan TC, Pearson ML, Silver LC and Jarvis WR: Guideline for prevention of surgical site infection, 1999. Centers for disease control and prevention (CDC) hospital infection control practices advisory committee. Am J Infect Control. 27:97–134; 96. 1999. View Article : Google Scholar : PubMed/NCBI
23	Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 25:1427–1433. 2010. View Article : Google Scholar : PubMed/NCBI
24	Shirai Y, Shiba H, Sakamoto T, Horiuchi T, Haruki K, Fujiwara Y, Futagawa Y, Ohashi T and Yanaga K: Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery. 158:360–365. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, Sharma R and Small D: The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 17:52–58. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S and Nakao A: Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 98:268–274. 2011. View Article : Google Scholar : PubMed/NCBI
27	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
28	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
29	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
30	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI